Wells Fargo & Company Rubius Therapeutics, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.14 - $0.31 $1 - $2	8 Added 2.61%	314 $0
Q3 2022 Nov 14, 2022	BUY	$0.46 - $1.29 $12 - $36	28 Added 10.07%	306 $0
Q2 2022 Aug 12, 2022	SELL	$0.79 - $5.98 $34,455 - $260,817	-43,615 Reduced 99.37%	278 $0
Q1 2022 May 16, 2022	SELL	$4.25 - $10.4 $59,024 - $144,435	-13,888 Reduced 24.04%	43,893 $242,000
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $99,704 - $182,721	10,300 Added 21.69%	57,781 $559,000
Q3 2021 Nov 15, 2021	BUY	$17.6 - $25.91 $38,843 - $57,183	2,207 Added 4.87%	47,481 $848,000
Q2 2021 Aug 16, 2021	BUY	$22.26 - $28.43 $843,765 - $1.08 Million	37,905 Added 514.38%	45,274 $1.11 Million
Q1 2021 May 13, 2021	SELL	$8.02 - $32.01 $192,704 - $769,136	-24,028 Reduced 76.53%	7,369 $195,000
Q4 2020 Feb 09, 2021	BUY	$4.23 - $8.73 $54,541 - $112,564	12,894 Added 69.69%	31,397 $238,000
Q3 2020 Nov 05, 2020	SELL	$4.65 - $6.25 $265 - $356	-57 Reduced 0.31%	18,503 $93,000
Q2 2020 Aug 13, 2020	SELL	$4.01 - $6.88 $1,880 - $3,226	-469 Reduced 2.46%	18,560 $111,000
Q1 2020 May 14, 2020	BUY	$3.74 - $9.84 $71,168 - $187,245	19,029 New	19,029 $84,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.